Platelet Activating Factor

A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.

Also Known As:

1-Alkyl-2-acetyl-sn-glycerophosphocholine; Platelet Aggregating Factor; Platelet Aggregation Enhancing Factor; Platelet-Activating Substance; Thrombocyte Aggregating Activity; 1 Alkyl 2 acetyl sn glycerophosphocholine; Aggregating Factor, Platelet; Factor, Platelet Activating; PAF Acether; Platelet Activating Substance; AGEPC; Acetyl Glyceryl Ether Phosphorylcholine; PAF-Acether; Phosphorylcholine, Acetyl Glyceryl Ether

Networked: 2984 relevant articles (68 outcomes, 303 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Antonopoulou, Smaragdi: 22 articles (01/2021 - 04/2002)
2.	Fragopoulou, Elizabeth: 17 articles (01/2021 - 04/2002)
3.	Demopoulos, Constantinos A: 16 articles (01/2021 - 04/2002)
4.	Travers, Jeffrey B: 14 articles (01/2021 - 05/2003)
5.	Shimizu, Takao: 13 articles (01/2021 - 01/2002)
6.	Bazan, Nicolas G: 12 articles (10/2020 - 07/2002)
7.	Ishii, Satoshi: 12 articles (02/2015 - 03/2002)
8.	McHowat, Jane: 11 articles (01/2019 - 04/2005)
9.	Bai, Huai: 10 articles (04/2020 - 11/2009)
10.	Fan, Ping: 10 articles (04/2020 - 11/2009)

Related Diseases

1.	Asthma (Bronchial Asthma) 04/01/1998 - "We conclude that SR 27417A is effective in inhibiting systemic, cellular and pulmonary effects after platelet-activating factor challenge in patients with mild bronchial asthma." 10/01/1992 - "Platelet-activating factor antagonists may partially be effective in asthma through inhibitory effects on neutrophil chemotaxis." 09/01/1999 - "The pathogenic role of platelet-activating factor (PAF) in asthma has been questioned due to the limited or negative efficacy of PAF antagonists; however, in acute asthma (AA), where the endogenous release of PAF may be enhanced, the effects of PAF antagonist receptors have not been investigated. " 03/15/2000 - "Numerous in vitro and in vivo studies in both animal models and human asthmatics have implicated platelet-activating factor (PAF) as an important inflammatory mediator in asthma. " 10/01/1994 - "This study compared the acute bronchial and hematologic effects of inhaled platelet activating factor (PAF) (30 micrograms as a single dose) in 19 patients with mild asthma and 19 normal subjects. "
2.	Anaphylaxis (Anaphylactic Shock) 08/01/1998 - "In order to find out anti-platelet activating factor (PAF) from natural resources, Korean medicinal plants used for the treatments of peripheral circulation disorders were tested for their possible protective effects on PAF-induced anaphylactic shock. " 01/01/2016 - "Platelet-activating factor shows some promise in the diagnosis of anaphylaxis. " 01/01/2022 - "In this study, we sought to prospectively assess involvement of key components of the platelet-activating factor pathway in pediatric patients with anaphylaxis. " 01/01/2011 - "Mechanistic studies showed that the food allergic systemic anaphylaxis was dependent on platelets, FcRγ and mast cells, and partially dependent on platelet activating factor and monocytes/macrophages, depending on mouse strain. " 09/01/2023 - "The aim of this review is to show that platelet-activating factor contributes to the development of severe anaphylactic reaction, and even to anaphylactic shock."
3.	Shock 09/01/1997 - "Treatment with a platelet-activating factor antagonist has little protective effects during endotoxic shock in the dog." 01/01/1997 - "This study aimed at evaluating the role of platelet-activating factor (PAF) on cardiovascular dysfunction in postischemic shock in pigs. " 01/01/1995 - "This study aimed at evaluating the role of platelet-activating factor (PAF) antagonism in haemorrhagic shock in juvenile pigs. " 08/01/1994 - "This study was designed to investigate the role of PAF blockade during experimental Gram-positive shock by pretreatment with platelet activating factor-antagonist (PAF-A). " 12/01/1992 - "[Experimental study on platelet activating factor and systemic circulatory failure caused by ischemic liver]."
4.	Ischemia 04/01/2000 - "The purpose of the present study was to determine if platelet-activating factor is an important mediator that produces vasospasm during reperfusion after ischemia in skeletal muscle. " 01/01/1996 - "The purpose of this study was to evaluate the renoprotective effect of a specific platelet-activating factor antagonist (WEB-2086) in an experimental model of normothermic renal ischemia. " 03/21/1994 - "This study investigated the distribution of platelet activating factor (PAF) binding sites in the brain and their involvement in global ischemia in a model of bilateral common carotid occlusion in the gerbil. " 02/01/1993 - "This study investigated the role of platelet-activating factor in the recruitment of polymorphonuclear neutrophils (PMN) in a rabbit model of cardiac ischemia and reperfusion. " 08/01/1990 - "The objective of this study was to determine whether platelet-activating factor (PAF) mediates the leukocyte-endothelial cell interactions elicited by ischemia/reperfusion. "
5.	Pancreatitis 07/01/2001 - "The effect of platelet-activating factor (PAF) in the pathogenesis of acute pancreatitis has been proved in various studies. " 06/01/1998 - "The initial studies on the therapeutic significance of lexipanphate-antagonist of platelet activating factor (PAF) in acute pancreatitis is promising. " 07/01/1993 - "This study demonstrates the formation of platelet-activating factor (PAF) in rats with acute experimental pancreatitis (AEP). " 10/01/1992 - "This study investigates the role of platelet-activating factor (PAF) in experimental pancreatitis. " 03/01/2009 - "Platelet-activating factor (PAF) has been implicated in the pathophysiologic events associated with acute pancreatitis. "

Related Drugs and Biologics

1.	WEB 2086 (apafant)
2.	Histamine (Histamine Dihydrochloride)
3.	epiyangambin
4.	Lipids
5.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
6.	Platelet Activating Factor
7.	Antigens
8.	Arachidonic Acid (Vitamin F)
9.	TCV 309
10.	Interleukins

Related Therapies and Procedures

1.	Therapeutics
2.	Resuscitation
3.	Intravenous Injections
4.	Intravenous Administration
5.	Injections